We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Mixed message

25 June 2014 By Neil Unmack, Chris Hughes

The U.S. drugmaker is marketing its $46 bln bid proposal direct to Shire investors. As bear hugs go, it’s soft. A price increase would have put more pressure on the target. AbbVie’s talk of material earnings gains in a deal implies a raise is possible – and may scare interlopers.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)